Hepatitis

The Skidki-na-vse® Hepatitis resource center provides clinical news and articles, pertaining to the Food and Drug Administration approved therapies to treat Hepatitis A, B, and C. Additionally, pharmacists will find coverage from pertinent conferences and meetings, videos, podcasts, and other associated content.

What can we help you find?
Transplantation of Hepatitis C-infected Kidneys Found Safe for Non-infected Patients
Transplanting organ from patients infected with hepatitis C could greatly expand the number of kidneys available and reduce wait times.
Trending News Today: FDA Identifies Risks with Some Hepatitis C Drugs
Top news of the day from across the health care landscape.
DAA Use in Hepatitis C Improves Survival for Patients with Previous Liver Cancer
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Trending News Today: Hepatitis C Linked with Higher Risk of Cardiovascular Disease
Top news of the day from across the health care landscape.
Hepatitis B Virus: Who Is at Risk, and What Can We Do?
The hepatitis B virus (HBV) is spread through with infected blood or bodily fluids, usually passing into a host via damaged skin (eg, lesions, needlesticks) or mucous membranes, such as the eyes or genitalia. 
Trending News Today: Louisiana, Asegua Partner for 5-Year Hepatitis C Treatment Plan
Top news of the day from across the health care landscape.
T-Cell Therapy Approach Shows Potential as Cure for Chronic Hepatitis B Virus
Receptor-modified T cells successfully controlled chronic hepatitis B virus, showing promise as a potential cure for the disease.
Trending News Today: Hepatitis B Vaccine Meets Primary Goal in Trial
Top news of the day from across the health care landscape.
Trending News Today: Americans with HBV, HCV Often Unaware of Infection
Top news of the day from across the health care landscape.
First Treatment for All Genotypes of Hepatitis C in Children Receives FDA Approval
This drug was previously approved, in 2017, to treat HCV in adults.
Study Examines HCV Retreatment Regimen in Patients with Previous Virologic Failure
Glecaprevir/pibrentasvir (G/P) sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
+ Load More